Logo image of RXDX

PROMETHEUS BIOSCIENCES INC (RXDX) Stock Fundamental Analysis

NASDAQ:RXDX - Nasdaq - US74349U1088 - Common Stock - Currency: USD

199.92  +0.18 (+0.09%)

After market: 199.95 +0.03 (+0.02%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RXDX. RXDX was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RXDX as it has an excellent financial health rating, but there are worries on the profitability. RXDX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RXDX has reported negative net income.
RXDX had a negative operating cash flow in the past year.
RXDX had negative earnings in each of the past 5 years.
In the past 5 years RXDX always reported negative operating cash flow.
RXDX Yearly Net Income VS EBIT VS OCF VS FCFRXDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -50M -100M

1.2 Ratios

RXDX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RXDX Yearly ROA, ROE, ROICRXDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RXDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXDX Yearly Profit, Operating, Gross MarginsRXDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

RXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RXDX has more shares outstanding
RXDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RXDX Yearly Shares OutstandingRXDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M 40M
RXDX Yearly Total Debt VS Total AssetsRXDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

An Altman-Z score of 94.07 indicates that RXDX is not in any danger for bankruptcy at the moment.
RXDX has a better Altman-Z score (94.07) than 99.20% of its industry peers.
RXDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 94.07
ROIC/WACCN/A
WACC8.62%
RXDX Yearly LT Debt VS Equity VS FCFRXDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 37.56 indicates that RXDX has no problem at all paying its short term obligations.
The Current ratio of RXDX (37.56) is better than 98.56% of its industry peers.
A Quick Ratio of 37.56 indicates that RXDX has no problem at all paying its short term obligations.
RXDX has a better Quick ratio (37.56) than 98.56% of its industry peers.
Industry RankSector Rank
Current Ratio 37.56
Quick Ratio 37.56
RXDX Yearly Current Assets VS Current LiabilitesRXDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for RXDX have decreased strongly by -26.62% in the last year.
The Revenue for RXDX has decreased by -36.47% in the past year. This is quite bad
RXDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 82.51% yearly.
EPS 1Y (TTM)-26.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.88%
Revenue 1Y (TTM)-36.47%
Revenue growth 3Y82.51%
Revenue growth 5YN/A
Sales Q2Q%-71.8%

3.2 Future

RXDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.32% yearly.
Based on estimates for the next years, RXDX will show a very strong growth in Revenue. The Revenue will grow by 145.93% on average per year.
EPS Next Y-16.9%
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
EPS Next 5Y22.32%
Revenue Next Year-69.44%
Revenue Next 2Y-47.62%
Revenue Next 3Y136.24%
Revenue Next 5Y145.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RXDX Yearly Revenue VS EstimatesRXDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
RXDX Yearly EPS VS EstimatesRXDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RXDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXDX Price Earnings VS Forward Price EarningsRXDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXDX Per share dataRXDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as RXDX's earnings are expected to decrease with -15.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%

More info and screens

0

5. Dividend

5.1 Amount

RXDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROMETHEUS BIOSCIENCES INC

NASDAQ:RXDX (6/15/2023, 8:23:19 PM)

After market: 199.95 +0.03 (+0.02%)

199.92

+0.18 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2023-05-09/amc
Earnings (Next)N/A N/A
Inst Owners0.05%
Inst Owner Change0%
Ins Owners24.07%
Ins Owner Change0%
Market Cap9.56B
Analysts72
Price Target198.9 (-0.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.21%
Max EPS beat(2)7.45%
EPS beat(4)4
Avg EPS beat(4)5.45%
Min EPS beat(4)2.44%
Max EPS beat(4)7.69%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)62.01%
Min Revenue beat(2)10.55%
Max Revenue beat(2)113.47%
Revenue beat(4)4
Avg Revenue beat(4)78.91%
Min Revenue beat(4)10.55%
Max Revenue beat(4)143.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2392.69
P/FCF N/A
P/OCF N/A
P/B 13.7
P/tB 13.7
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)-4.66
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.08
BVpS14.59
TBVpS14.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 293.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.56
Quick Ratio 37.56
Altman-Z 94.07
F-Score3
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)350.62%
Cap/Depr(5y)510.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.88%
EPS Next Y-16.9%
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
EPS Next 5Y22.32%
Revenue 1Y (TTM)-36.47%
Revenue growth 3Y82.51%
Revenue growth 5YN/A
Sales Q2Q%-71.8%
Revenue Next Year-69.44%
Revenue Next 2Y-47.62%
Revenue Next 3Y136.24%
Revenue Next 5Y145.93%
EBIT growth 1Y-50.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.98%
EBIT Next 3Y-23.62%
EBIT Next 5Y28.62%
FCF growth 1Y-94.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.09%
OCF growth 3YN/A
OCF growth 5YN/A